CompletedEUCTR 2014-001211-39
A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Addiction
This historical record does not confirm current site availability.
Historical research recordBulgaria + Poland
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
- Listed locations
- Bulgaria · Poland
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 450
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Bulgaria, Poland
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2014-001211-39
- Official title
Show the full official title
A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder
Recruitment & locations
CompletedBulgaria · Poland
Questions about this study
Who is behind this study?
The study sponsor is Alkermes, Inc.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me